| 26.68 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 31.24 | 1-year : | 31.41 |
| Resists | First : | 26.75 | Second : | 26.89 |
| Pivot price | 26.68 | |||
| Supports | First : | 26.51 | Second : | 22.05 |
| MAs | MA(5) : | 26.68 | MA(20) : | 26.68 |
| MA(100) : | 26.68 | MA(250) : | 24.8  |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 43.5 | D(3) : | 43.5 |
| RSI | RSI(14): 77.7 | |||
| 52-week | High : | 26.89 | Low : | 11.02 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZGNX ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 26.96 - 27.1 | 27.1 - 27.2 |
| Low: | 26.14 - 26.32 | 26.32 - 26.47 |
| Close: | 26.43 - 26.7 | 26.7 - 26.92 |
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Mon, 07 Mar 2022
UCB Completes Acquisition of Zogenix, Inc. - PR Newswire
Tue, 01 Feb 2022
UCB Commences Tender Offer to Acquire Zogenix, Inc. - UCB
Thu, 20 Jan 2022
Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar? - Yahoo Finance
Wed, 19 Jan 2022
UCB to Buy Epilepsy Drugmaker Zogenix for Up to $1.9 Billion - Bloomberg
Wed, 19 Jan 2022
UCB to acquire Zogenix - UCB
Mon, 29 Nov 2021
Do Analysts Expect Zogenix, Inc. (ZGNX) Stock to Rise After It Is Lower By -25.44% in a Month? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 107.2 (%) |
| Shares Short | 5,890 (K) |
| Shares Short P.Month | 6,540 (K) |
| EPS | -4.35 |
| EPS Est Next Qtrly | -0.93 |
| EPS Est This Year | -3.62 |
| EPS Est Next Year | -3.46 |
| Book Value (p.s.) | 4.01 |
| Profit Margin | 0 % |
| Operating Margin | -344 % |
| Return on Assets (ttm) | -23 % |
| Return on Equity (ttm) | -75.1 % |
| Qtrly Rev. Growth | 690.5 % |
| Gross Profit (p.s.) | -2.24 |
| Sales Per Share | 1.13 |
| EBITDA (p.s.) | -3.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -182 (M) |
| Levered Free Cash Flow | -97 (M) |
| PE Ratio | -6.14 |
| PEG Ratio | 0 |
| Price to Book value | 6.65 |
| Price to Sales | 23.49 |
| Price to Cash Flow | -8.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|